223 related articles for article (PubMed ID: 8962247)
1. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
[No Abstract] [Full Text] [Related]
2. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.
Wabbijn M; Balk AH; van Domburg RT; Vantrimpont PJ; van Riemsdijk IC; Baan CC; Weimar W; van Gelder T
Exp Clin Transplant; 2004 Jun; 2(1):201-7. PubMed ID: 15859929
[TBL] [Abstract][Full Text] [Related]
4. Incidence and impact of acute rejection episodes on short- and long-term graft survival in recipients of simultaneous pancreas-kidney transplantation.
Cantarovich D; Giral M; Josien R; Karam G; Hourmant M; Dantal J; Blancho G; Soulillou JP
Transplant Proc; 1995 Feb; 27(1):1319. PubMed ID: 7878897
[No Abstract] [Full Text] [Related]
5. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
[No Abstract] [Full Text] [Related]
6. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.
Cahn JY; Bordigoni P; Tiberghien P; Milpied N; Brion A; Widjenes J; Lioure B; Michel G; Burdach S; Kolb HJ
Transplantation; 1995 Nov; 60(9):939-42. PubMed ID: 7491697
[TBL] [Abstract][Full Text] [Related]
7. Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years.
MacDonell RC; Van Buren DH; Richie RE; Johnson HK; Nylander WA; Helderman JH; Ynares CM; Trusler LA; Green WF; Crowe DA
Transplant Proc; 1994 Oct; 26(5):2518-21. PubMed ID: 7940774
[No Abstract] [Full Text] [Related]
8. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
[No Abstract] [Full Text] [Related]
9. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.
van Gelder T; Knoop CJ; Hesse CJ; Vaessen LM; Balk AH; Yzermans JN; Weimar W
Transplant Proc; 1995 Feb; 27(1):856-8. PubMed ID: 7879206
[No Abstract] [Full Text] [Related]
11. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
[No Abstract] [Full Text] [Related]
12. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials.
Adu D; Cockwell P; Ives NJ; Shaw J; Wheatley K
BMJ; 2003 Apr; 326(7393):789. PubMed ID: 12689974
[TBL] [Abstract][Full Text] [Related]
13. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine therapy in pancreas transplantation.
Davidson I; Lu C; Melone D; Risser R
Transplant Proc; 1996 Aug; 28(4):2134-5. PubMed ID: 8769179
[No Abstract] [Full Text] [Related]
15. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
Koga A; Moreso FJ; Seron D; Gil-Vernet S; Cruzado JM; Castelao AM; Grinyó JM
Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318
[TBL] [Abstract][Full Text] [Related]
17. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
[TBL] [Abstract][Full Text] [Related]
18. Six-year experience with a triple drug protocol in renal transplantation: analysis of risk factors.
Pallardó LM; Sánchez P; Sánchez J; García J; Orero E; Beneyto I; Cruz JM
Transplant Proc; 1992 Dec; 24(6):2714-5. PubMed ID: 1465911
[No Abstract] [Full Text] [Related]
19. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
[No Abstract] [Full Text] [Related]
20. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
